Navigation Links
Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011
Date:2/10/2011

IAFLEX;
  • the ability and timing to complete enrollment, and report top-line results, of the phase III double blind trials for XIAFLEX for the treatment of Peyronie's disease, and the size of the Peyronie's market; and,
  • the interpretation and impact of the FDA's response to  Citizen Petitions on the testosterone gel market.

  • Forward-looking statements often address Auxilium's expected future financial position or business strategy and plans and objectives of management for future operations, and often contain the words "believe," "may," "could," "will," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," and "potentially," and similar expressions. Forward-looking statements provide Auxilium's current expectations or forecasts of future events. Auxilium's performance and financial results could differ materially from those reflected in these forward-looking statements due to:

  • the success of research and development activities;
  • further evaluation of clinical data and results of clinical trials;
  • the performance of third-party partners, manufacturers, suppliers and licensees;
  • decisions by regulatory authorities as to whether and when to approve drug applications;
  • decisions by regulatory authorities as to whether and when to proceed to the next phase of clinical trials;
  • difficulties or delays in manufacturing;
  • the outcome of pending litigation;
  • competition from currently marketed products, generic products, and new products;
  • general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and the jurisdictions in which Auxilium markets or seeks to market its products;
  • claims and concerns that may arise regarding the safety or efficacy of its products; and
  • increases in costs or expenses.

  • A more detailed list and description of the risks and uncertainties that Au
    '/>"/>

    SOURCE Auxilium Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011
    2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
    3. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
    4. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
    5. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
    6. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
    7. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
    8. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
    9. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
    10. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
    11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/27/2015)... 27, 2015  For about a century, a ... ability to utilize and catabolize glucose at a ... is called the ,Warburg phenomenon", that is an ... oxygen presence, leading to enhanced lactate generation. Even ... choose glucose fermentation. A variety of such abnormalities ...
    (Date:4/27/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... year ended December 31, 2014. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... provide the outcome management and investors had hoped ... Therapeutics", said Andrew Rae , President & ...
    (Date:4/27/2015)... HEIDELBERG , Alemania, April 27, 2015 ... patente para un nuevo receptor utilizando tecnología de descubrimiento ... no cubierta en el tratamiento de millones de pacientes ... anunciado hoy que ha recibido una patente en Europa ... el descubrimiento de Molecular Health de que EPHB4 es ...
    (Date:4/27/2015)... Calif. (PRWEB) April 27, 2015 Dr. ... drug and chemical toxicity carries implications for advancing the ... April 28 at National University , the second-largest ... presentation by Dr. Hanzlik, a professor at the University ... metabolism and drug design, starts at 5 p.m. and ...
    Breaking Biology Technology:Study Indicates Cancer Cells Alter Glucose Metabolism to Enhance Energy Production and Cell Growth 2iCo Therapeutics Announces Year End 2014 Financial Results 2iCo Therapeutics Announces Year End 2014 Financial Results 3iCo Therapeutics Announces Year End 2014 Financial Results 4Molecular Health obtiene la patente para un nuevo receptor 2Molecular Health obtiene la patente para un nuevo receptor 3Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3
    ... Solution innovating the way Misukanis & Odden schedule tasks. , ... ... ( http://info.oneplacehome.com ), creators of the ground breaking OnePlace ... their video series "A Day In The Life." The newest level ...
    ... Ichijo and Mano Receive 2008 JCA-Mauvernay Award, ... Group,(Debiopharm), a global biopharmaceutical development specialist that,focuses ... presented,Professors Hidenori Ichijo and Hiroyuki Mano with ... and applied research work in oncology.,The Awards ...
    ... 510(k) Clearance from ... - Development Progress Triggered $1M Milestone Payment from Cook Medical - ... at 4:30 p.m. Eastern Time -, REDWOOD CITY, Calif., October 28 ... progress,for its fiscal 2009 first quarter ended September 30, 2008., "We ...
    Cached Biology Technology:Riverock Technologies Helps Misukanis & Odden Eliminate Task Management Obstacles 2Riverock Technologies Helps Misukanis & Odden Eliminate Task Management Obstacles 3Japanese Cancer Association and Debiopharm Honour Japanese Research 2Japanese Cancer Association and Debiopharm Honour Japanese Research 3Cardica Announces Fiscal 2009 First Quarter Financial Results 2Cardica Announces Fiscal 2009 First Quarter Financial Results 3Cardica Announces Fiscal 2009 First Quarter Financial Results 4Cardica Announces Fiscal 2009 First Quarter Financial Results 5Cardica Announces Fiscal 2009 First Quarter Financial Results 6
    (Date:4/27/2015)... , April 27, 2015  For more than ... trade show has been the premier worldwide event for ... 2015 is a must-attend event for any local, national, ... into the emerging commercial markets and current applications of ... innovations of this projected $48 billion industry, and how ...
    (Date:4/27/2015)... 27, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces that ... customers the first week of May, 2015 and will ... May. Gino Pereira , Chief ... the company as Wocket® enters the consumer market. We ...
    (Date:4/27/2015)... 27, 2015 Profile Solutions, Inc. (OTC: PSIQ), ... systems is pleased to announce that Dr Gerry ... and member of its scientific advisory board. ... a thought leader in technology-enhanced learning models. He was ... has published studies and books focused on online student ...
    Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
    ... than the rural vegetated areas around them, but how much ... been a matter of debate. Now a study by Stanford ... the first time, showing that it is modest compared with ... and 4 percent of the gross global warming since the ...
    ... closer to understanding one of nature,s most extraordinary sights ... olive ridley sea turtles. The new study, published today ... Ecology , is the first to combine three different ... should help conserve these vulnerable marine creatures. The ...
    ... Supercomputer Center (SDSC) and the California Institute for ... of California, San Diego, have been awarded a ... Foundation (NSF) to create a Kepler Scientific Workflow ... to help manage ever-growing data sets used in ...
    Cached Biology News:Urban 'heat island' effect is a small part of global warming; white roofs don't reduce it 2Urban 'heat island' effect is a small part of global warming; white roofs don't reduce it 3How learning more about mass nesting can help conserve sea turtles 2SDSC, Calit2 awarded $1.4 million NSF grant for new bioinformatics tools 2SDSC, Calit2 awarded $1.4 million NSF grant for new bioinformatics tools 3
    COMING SOON: Anti-Mouse C5/C5b, Clone BB5.1. Monoclonal Antibody...
    ... Goat anti-Human Alpha 1 Acid ... azide Goats were immunized ... glycoprotein in Freund's adjuvant. ... absorbed to ensure specificity. ...
    Anti-Mouse Valpha 2 TCR, Purified (Clone B20.1) (rat IgG2a)...
    Request Info...
    Biology Products: